DGAP-News: Sangui BioTech International Inc. files comprehensive new patent application significantly expanding the protection of its hemoglobin formulations
(firmenpresse) - DGAP-News: Sangui BioTech International Inc. / Key word(s): Patent
Sangui BioTech International Inc. files comprehensive new patent
application significantly expanding the protection of its hemoglobin
formulations
04.09.2013 / 15:30
---------------------------------------------------------------------
Sangui BioTech files comprehensive new patent application significantly
expanding the protection of its hemoglobin formulations
Witten, Germany, September 4, 2013
Sangui BioTech GmbH has filed another patent application with the German
Patent Office (DPMA) in Munich; international applications are planned to
follow. The patent application is to significantly expand the protection of
the hemoglobin formulations developed by Sangui. It will encompass a
greater array of ischemic conditions of the human body, for instance in the
case of severe dysfunctions of the lung. If the treatment described in the
patent application will successfully pass clinical development it can help
save human lives in intensive care units bridging the existing gap between
high pressure respiration and the costly and high-risk extra-corporeal
blood oxygenation (in the 'lung'-section of a life support machine).
The patent application also protects the option to seek new opportunities
for a fast track authorization of hemoglobin formulations aiming at such
indications with a high mortality.
Sangui BioTech International, Inc. ('SGBI') is a holding company the shares
of which are being traded on the OTCQB marketplace (www.otcmarkets.com:
SGBI) and the OTC markets of Berlin and Hamburg-Hannover stock exchanges.
Its purpose is to provide financing and access to the capital markets for
the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent
subsidiary of Sangui BioTech International, Inc.
For more information please contact:
Joachim Fleing
Phone: +49 (179) 7963472
Fax: +49 (2302) 915191
e-mail: fleing(at)sangui.de
Some of the statements contained in this news release discuss future
expectations, contain projections of results of operation or financial
condition or state other 'forward-looking' information. These statements
are subject to known and unknown risks, uncertainties, and other factors
that could cause the actual results to differ materially from those
contemplated by the statements. The forward-looking information is based on
various factors and is derived using numerous assumptions. Important
factors that may cause actual results to differ from projections include,
among many others, the ability of the Company to raise sufficient capital
to meet operating requirements. Words such as 'anticipates,' 'expects,'
'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and variations of
such words and similar expressions are intended to identify such
forward-looking statements. Unless required by law, the Company undertakes
no obligation to update publicly any forward-looking statements, whether as
a result of new information, future events or otherwise.
End of financial news
---------------------------------------------------------------------
04.09.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
229025 04.09.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 04.09.2013 - 15:30 Uhr
Sprache: Deutsch
News-ID 293417
Anzahl Zeichen: 2955
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 361 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Sangui BioTech International Inc. files comprehensive new patent application significantly expanding the protection of its hemoglobin formulations"
steht unter der journalistisch-redaktionellen Verantwortung von
Sangui BioTech International Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
